Dual-targeting prodrug nanotheranostics for NIR-II fluorescence imaging-guided photo-immunotherapy of glioblastoma
文献类型：期刊论文
| 作者 | Li, Fenglin2; Lai, Yi1; Ye, Jiayi1; Saeed, Madiha1; Dang, Yijing2; Zou, Zhifeng2; Chen, Fangmin1; Zhang, Wen2; Xu, Zhiai2 |
| 刊名 | ACTA PHARMACEUTICA SINICA B
 |
| 出版日期 | 2022-09-01 |
| 卷号 | 12期号:9页码:3486-3497 |
| ISSN号 | 2211-3835 |
| 关键词 | Glioblastoma Dual targeting Photothermal therapy NIR-II fluorescence imaging Precise immunotherapy |
| DOI | 10.1016/j.apsb.2022.05.016 |
| 通讯作者 | Xu, Zhiai(zaxu@chem.ecnu.edu.cn) |
| 英文摘要 | Glioblastoma (GBM) therapy is severely impaired by the blood-brain barrier (BBB) and invasive tumor growth in the central nervous system. To improve GBM therapy, we herein presented a dual-targeting nanotheranostic for second near-infrared (NIR-II) fluorescence imaging-guided photo-immunotherapy. Firstly, a NIR-II fluorophore MRP bearing donor-acceptor-donor (D-A-D) backbone was synthesized. Then, the prodrug nanotheranostics were prepared by self-assembling MRP with a pro -drug of JQ1 (JPC) and T7 ligand-modified PEG5k-DSPE. T7 can cross the BBB for tumor-targeted de-livery of JPC and MRP. JQ1 could be restored from JPC at the tumor site for suppressing interferon gamma-inducible programmed death ligand 1 expression in the tumor cells. MRP could generate NIR-II fluorescence to navigate 808 nm laser, induce a photothermal effect to trigger in-situ antigen release at the tumor site, and ultimately elicit antitumor immunogenicity. Photo-immunotherapy with JPC and MRP dual-loaded nanoparticles remarkably inhibited GBM tumor growth in vivo. The dual-targeting na-notheranostic might represent a novel nanoplatform for precise photo-immunotherapy of GBM.(c) 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| WOS关键词 | PHOTOTHERMAL THERAPY ; NANOPARTICLES ; RESISTANCE ; RESECTION ; SURVIVAL |
| 资助项目 | National Natural Science Foundation of China[22074043] ; National Natural Science Foundation of China[22174047] ; National Natural Science Foundation of China[32050410287] ; Science and Technology Commission of Shanghai Municipality (China)[20142202800] ; China Postdoctoral Science Foundation[2021M700157] ; Shanghai Post-Doctoral Excellence Program (China)[2021424] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| 出版者 | INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES |
| WOS记录号 | WOS:000864826500004 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/303130]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Xu, Zhiai |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res & Ctr Pharmaceut, Shanghai 201203, Peoples R China 2.East China Normal Univ, Sch Chem & Mol Engn, Shanghai 200241, Peoples R China |
| 推荐引用方式 GB/T 7714 | Li, Fenglin,Lai, Yi,Ye, Jiayi,et al. Dual-targeting prodrug nanotheranostics for NIR-II fluorescence imaging-guided photo-immunotherapy of glioblastoma[J]. ACTA PHARMACEUTICA SINICA B,2022,12(9):3486-3497. |
| APA | Li, Fenglin.,Lai, Yi.,Ye, Jiayi.,Saeed, Madiha.,Dang, Yijing.,...&Xu, Zhiai.(2022).Dual-targeting prodrug nanotheranostics for NIR-II fluorescence imaging-guided photo-immunotherapy of glioblastoma.ACTA PHARMACEUTICA SINICA B,12(9),3486-3497. |
| MLA | Li, Fenglin,et al."Dual-targeting prodrug nanotheranostics for NIR-II fluorescence imaging-guided photo-immunotherapy of glioblastoma".ACTA PHARMACEUTICA SINICA B 12.9(2022):3486-3497. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。